HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPa-CD47, PD-1/PD-L1, and TGFB; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel tri-specific […]